Wednesday, November 25, 2015

An FDA for the financial world?

Two U. of Chicago professors say the financial services industry should be regulated by an agency akin to the U.S. Food and Drug Administration with new products, like derivatives, subject to review and approval.

An FDA for the financial world?


Gretchen Morgenson, a 2002 Pulitzer Prize winner, writes a must-read column in the New York Times Sunday business section. She often sheds light on malfeasance in the financial services industry. She has a habit of noting that big banks scream against government involvement and regulation, except when they need the government to bail them out because their derivative bets went bad.

Sunday's column involved an interview with two University of Chicago professors who recently published a paper with a thesis that suggested aspects of the banking industry should be regulated by an organization like the U.S. Food and Drug Administration.

Basically, each new derivative - credit default swaps, for example - would be evaluated like a new drug to measure the speculative nature and possible adverse side effects of the product.

The link to the column is here.

The link to the paper, via the University of Chicago Institute for Law & Economics and the Social Science Research Network, is here.

Eric A. Posner is a law professor and Glen E. Weyl is an assistant economics professor.

In the abstract, they suggest:

"The financial crisis of 2008 was caused in part by speculative investment in complex derivatives. In enacting the Dodd-Frank Act, Congress sought to address the problem of speculative investment, but merely transferred that authority to various agencies, which have not yet found a solution. We propose that when firms invent new financial products, they be forbidden to sell them until they receive approval from a government agency designed along the lines of the FDA, which screens pharmaceutical innovations."

Inquirer Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Inquirer Staff Writer
Also on
letter icon Newsletter